JP2013507371A - Ｇタンパク質共役受容体８８の調節因子 - Google Patents
Ｇタンパク質共役受容体８８の調節因子 Download PDFInfo
- Publication number
- JP2013507371A JP2013507371A JP2012533272A JP2012533272A JP2013507371A JP 2013507371 A JP2013507371 A JP 2013507371A JP 2012533272 A JP2012533272 A JP 2012533272A JP 2012533272 A JP2012533272 A JP 2012533272A JP 2013507371 A JP2013507371 A JP 2013507371A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- methyl
- mmol
- alkoxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XHQVAHSQBATIAY-LDFQAZLFSA-N CC[C@H](C)[C@@H](CN(C([C@H](C1)[C@@H]1c(nc1)ccc1F)=O)c1ccc(cc(C2CC2)cc2)c2c1)N Chemical compound CC[C@H](C)[C@@H](CN(C([C@H](C1)[C@@H]1c(nc1)ccc1F)=O)c1ccc(cc(C2CC2)cc2)c2c1)N XHQVAHSQBATIAY-LDFQAZLFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25009109P | 2009-10-09 | 2009-10-09 | |
| US61/250,091 | 2009-10-09 | ||
| PCT/US2010/051597 WO2011044212A1 (en) | 2009-10-09 | 2010-10-06 | Modulators of g protein-coupled receptor 88 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507371A true JP2013507371A (ja) | 2013-03-04 |
| JP2013507371A5 JP2013507371A5 (enExample) | 2013-11-21 |
Family
ID=43479451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012533272A Pending JP2013507371A (ja) | 2009-10-09 | 2010-10-06 | Ｇタンパク質共役受容体８８の調節因子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8426414B2 (enExample) |
| EP (1) | EP2486014B1 (enExample) |
| JP (1) | JP2013507371A (enExample) |
| CN (1) | CN102648180A (enExample) |
| ES (1) | ES2430946T3 (enExample) |
| WO (1) | WO2011044212A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| JP2016523963A (ja) | 2013-07-08 | 2016-08-12 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | アリールアミドキナーゼ阻害剤 |
| EP3054955B1 (en) | 2013-10-11 | 2018-05-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| IL277495B2 (en) | 2018-03-23 | 2024-08-01 | Carmot Therapeutics Inc | Modulators of protein-coupled receptors - G |
| MX2023006123A (es) * | 2020-11-25 | 2023-06-02 | Reneo Pharmaceuticals Inc | Metodos para elaborar un agonista de ppar-delta. |
| EP4263492B1 (en) | 2020-12-17 | 2025-04-09 | ACADIA Pharmaceuticals Inc. | Modulators of g protein-coupled receptor 88 |
| EP4337682A2 (en) | 2021-05-13 | 2024-03-20 | Carmot Therapeutics Inc. | Modulators of g-protein coupled receptors |
| GB202209193D0 (en) | 2022-06-22 | 2022-08-10 | Pandeia Therapeutics Ltd | Modulators of g protein-coupled receptor 88 |
| GB202209195D0 (en) | 2022-06-22 | 2022-08-10 | Pandeia Therapeutics Ltd | Modulators of g protein-coupled receptor 88 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008525350A (ja) * | 2004-12-23 | 2008-07-17 | ノバルティス アクチエンゲゼルシャフト | レニンの活性に依存する疾患の処置のためのピロリジン誘導体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2400368A1 (en) | 1992-12-02 | 1994-06-09 | Allen J. Duplantier | Catechol diethers as selective pde iv inhibitors |
| US5709861A (en) | 1993-04-22 | 1998-01-20 | Emisphere Technologies, Inc. | Compositions for the delivery of antigens |
| EP1495009B1 (en) | 2002-04-05 | 2008-03-12 | Boehringer Ingelheim Pharmaceuticals Inc. | Cyanamides useful as reversible inhibitors of cysteine proteases |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| AU2003295781A1 (en) | 2002-11-22 | 2004-06-18 | Bristol-Myers Squibb Company | Arylcyclopropylcarboxylic amides as potassium channel openers |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| WO2004072018A1 (ja) | 2003-02-12 | 2004-08-26 | Takeda Pharmaceutical Company Limited | アミン誘導体 |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| US7834013B2 (en) | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
| CA2570694A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| JP2008512417A (ja) | 2004-09-10 | 2008-04-24 | ユセベ ファルマ ソシエテ アノニム | シグマ受容体リガンド |
| CN100494167C (zh) | 2005-08-02 | 2009-06-03 | 天津大学 | 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用 |
| JP2007217408A (ja) | 2006-01-19 | 2007-08-30 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| PL2007756T3 (pl) | 2006-04-07 | 2016-01-29 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
| WO2007129188A1 (en) | 2006-05-10 | 2007-11-15 | Pfizer Japan Inc. | Cyclopropanecarboxamide compound |
| US20080039535A1 (en) | 2006-08-14 | 2008-02-14 | Wyeth | Methods of identifying agents for treating neurological disorders |
| US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
| US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
-
2010
- 2010-10-04 US US12/897,004 patent/US8426414B2/en active Active
- 2010-10-06 JP JP2012533272A patent/JP2013507371A/ja active Pending
- 2010-10-06 ES ES10765716T patent/ES2430946T3/es active Active
- 2010-10-06 CN CN2010800560408A patent/CN102648180A/zh active Pending
- 2010-10-06 WO PCT/US2010/051597 patent/WO2011044212A1/en not_active Ceased
- 2010-10-06 EP EP10765716.5A patent/EP2486014B1/en not_active Not-in-force
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008525350A (ja) * | 2004-12-23 | 2008-07-17 | ノバルティス アクチエンゲゼルシャフト | レニンの活性に依存する疾患の処置のためのピロリジン誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011044212A1 (en) | 2011-04-14 |
| US20110251204A1 (en) | 2011-10-13 |
| US8426414B2 (en) | 2013-04-23 |
| EP2486014A1 (en) | 2012-08-15 |
| EP2486014B1 (en) | 2013-07-31 |
| ES2430946T3 (es) | 2013-11-22 |
| CN102648180A (zh) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507371A (ja) | Ｇタンパク質共役受容体８８の調節因子 | |
| US8497271B2 (en) | Modulators of G protein-coupled receptor 88 | |
| US8304577B2 (en) | Modulators of G protein-coupled receptor 88 | |
| US11572374B2 (en) | N-cyano-7-azanorbornane derivatives and uses thereof | |
| BG107229A (bg) | Циклопентил-заместени глутарамидни производни като инхибитори на неутрална ендопептидаза | |
| CN101516360A (zh) | 用于治疗疾病的取代的炔属化合物 | |
| KR20230104191A (ko) | 질환 치료를 위한 이환식 화합물 및 그 용도 | |
| JP2023510746A (ja) | Ｓｍａｒｃａ２－ｖｈｌ分解剤 | |
| IL322853A (en) | History of 1-(([1,1'-biphenyl]-2-yl)sulfonyl)-4-fluoro-n-(3-(methylsulfonyl)allyl)piperidine-4-carboxamide as ras-pi3k modulators for exemplary cancer therapy | |
| CA2853006A1 (en) | Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection | |
| WO2017025523A1 (en) | Pyridine and pyrimidine derivatives | |
| TW201313684A (zh) | 氮雜螺烷烴化合物 | |
| CN102971286B (zh) | 用于治疗例如自身免疫病症、过敏和慢性疼痛病状的新组织蛋白酶s蛋白酶抑制剂 | |
| WO2023114456A1 (en) | Uses of bicyclic compounds for the treatment of diseases | |
| WO2023215376A1 (en) | Methods of treating neuropathies | |
| EP3009421A1 (en) | Glycine transporter inhibitor | |
| US20250312335A1 (en) | Flt combination therapy for cancer and compositions therefor | |
| ZA200300121B (en) | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase. | |
| HK1178878A (en) | New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131001 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131001 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20141016 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150512 |